Pages that link to "Q85620133"
Jump to navigation
Jump to search
The following pages link to Steven M Horwitz (Q85620133):
Displaying 50 items.
- Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies (Q33369463) (← links)
- Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study (Q33393701) (← links)
- Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma (Q33400117) (← links)
- Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma (Q33404875) (← links)
- Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma (Q33417976) (← links)
- Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. (Q33423638) (← links)
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. (Q33423816) (← links)
- A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial (Q33428066) (← links)
- The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma (Q33440251) (← links)
- Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses (Q33592768) (← links)
- NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas (Q34102089) (← links)
- Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study (Q34226010) (← links)
- Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification (Q34365008) (← links)
- Primary cutaneous B-cell lymphomas: part II. Therapy and future directions (Q34365013) (← links)
- A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. (Q34663596) (← links)
- Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. (Q35218651) (← links)
- Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. (Q35586880) (← links)
- How I treat the peripheral T-cell lymphomas (Q35865090) (← links)
- Survivorship care planning after participation in communication skills training intervention for a consultation about lymphoma survivorship (Q36307935) (← links)
- Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial (Q36671582) (← links)
- Non-Hodgkin's lymphomas, version 4.2014. (Q36820885) (← links)
- Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 (Q36826893) (← links)
- Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies (Q36836080) (← links)
- Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma (Q36914387) (← links)
- Protocol for a cluster randomised trial of a communication skills intervention for physicians to facilitate survivorship transition in patients with lymphoma (Q37063580) (← links)
- Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model (Q37163606) (← links)
- Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors (Q37296614) (← links)
- Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project (Q37384289) (← links)
- The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice (Q37526352) (← links)
- 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. (Q37561054) (← links)
- Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma (Q37609238) (← links)
- Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. (Q37609681) (← links)
- Central nervous system involvement in T-cell lymphoma: A single center experience (Q37733139) (← links)
- Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers (Q38179568) (← links)
- Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials (Q38379898) (← links)
- Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides (Q38813983) (← links)
- Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population (Q38835470) (← links)
- Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States (Q38956577) (← links)
- mTOR inhibition in T-cell lymphoma: a path(way) forward. (Q38983715) (← links)
- Targeting histone deacetylases in T-cell lymphoma (Q38998630) (← links)
- T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment (Q39063866) (← links)
- Long-term follow-up and management of small and medium-sized CD4+ T cell lymphoma and CD8+ lymphoid proliferations of acral sites: a multicenter experience (Q39638333) (← links)
- A prospective cohort study of patients with peripheral T-cell lymphoma in the United States (Q40444551) (← links)
- Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma (Q40929539) (← links)
- Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. (Q41108261) (← links)
- Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: a single-center, retrospective study (Q41629780) (← links)
- Communication between oncologists and lymphoma survivors during follow-up consultations: A qualitative analysis (Q41675303) (← links)
- Primary cutaneous marginal zone lymphoma with leptomeningeal involvement and a durable response to rituximab (Q42135204) (← links)
- Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial (Q42360313) (← links)
- A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score (Q43011827) (← links)